Brief: Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv
18/05/2026 14:07
May 18 (Reuters) - Dare Bioscience Inc DARE.O: DARÉ BIOSCIENCE INITIATES PHASE 2 STUDY OF DARE-HPV, A NOVEL PHARMACOLOGIC TREATMENT FOR PERSISTENT HIGH-RISK HPV INFECTION WITH NO FDA-APPROVED THERAPIES DARE BIOSCIENCE INC - DARE-HPV DEVELOPMENT SUPPORTED BY $10 MILLION ARPA-H CONTRACT; TOPLINE DATA EXPECTED IN 2027 DARE BIOSCIENCE INC - PHASE 2 STUDY TO ENROLL ABOUT 100 WOMEN OVER UP TO 21 DAYS Source text: ID:nGNX1J9JqK Further company coverage: DARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dare Bioscience
See all newsBrief: Dare Bioscience - Files For Resale Of Up To 8,934,345 Shares Of Common Stock - SEC Filing
Brief: Daré Bioscience CEO Sabrina Martucci Johnson Named To Forbes 2026 “50 Over 50 Innovation” List
NASDAQ RESUMED AT 12:50 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:45 PM
Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary